AstraZeneca PLC (AZN)
166.71
+0.73
(+0.44%)
USD |
NYSE |
Aug 24, 16:00
165.50
-1.21
(-0.73%)
Pre-Market: 05:00
AstraZeneca Enterprise Value : 543.37B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 543.37B |
| August 21, 2026 | 541.11B |
| August 20, 2026 | 536.49B |
| August 19, 2026 | 537.91B |
| August 18, 2026 | 522.87B |
| August 17, 2026 | 512.91B |
| August 14, 2026 | 511.55B |
| August 13, 2026 | 514.00B |
| August 12, 2026 | 517.91B |
| August 11, 2026 | 518.68B |
| August 10, 2026 | 528.48B |
| August 07, 2026 | 526.97B |
| August 06, 2026 | 525.88B |
| August 05, 2026 | 527.21B |
| August 04, 2026 | 508.98B |
| August 03, 2026 | 516.26B |
| July 31, 2026 | 552.46B |
| July 30, 2026 | 557.73B |
| July 29, 2026 | 563.81B |
| July 28, 2026 | 561.27B |
| July 27, 2026 | 552.46B |
| July 24, 2026 | 551.28B |
| July 23, 2026 | 548.21B |
| July 22, 2026 | 552.74B |
| July 21, 2026 | 551.53B |
| Date | Value |
|---|---|
| July 20, 2026 | 536.58B |
| July 17, 2026 | 550.17B |
| July 16, 2026 | 551.38B |
| July 15, 2026 | 548.52B |
| July 14, 2026 | 536.52B |
| July 13, 2026 | 551.93B |
| July 10, 2026 | 558.57B |
| July 09, 2026 | 579.91B |
| July 08, 2026 | 613.38B |
| July 07, 2026 | 625.29B |
| July 06, 2026 | 616.11B |
| July 02, 2026 | 631.58B |
| July 01, 2026 | 596.57B |
| June 30, 2026 | 614.43B |
| June 29, 2026 | 618.56B |
| June 26, 2026 | 610.68B |
| June 25, 2026 | 602.21B |
| June 24, 2026 | 593.96B |
| June 23, 2026 | 587.76B |
| June 22, 2026 | 573.52B |
| June 18, 2026 | 568.87B |
| June 17, 2026 | 578.05B |
| June 16, 2026 | 580.59B |
| June 15, 2026 | 576.13B |
| June 12, 2026 | 580.72B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| GSK Plc | 124.20B |
| Johnson & Johnson | 685.82B |
| Eli Lilly & Co. | 1.220T |
| Merck & Co., Inc. | 418.70B |
| Novo Nordisk A/S | 171.54B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.076B |
| Revenue (Quarterly) | 15.26B |
| Total Expenses (Quarterly) | 12.19B |
| EPS Diluted (Quarterly) | 0.9849 |
| Gross Profit Margin (Quarterly) | 76.09% |
| Profit Margin (Quarterly) | 20.15% |
| Earnings Yield | 2.00% |
| Operating Earnings Yield | 2.70% |
| Normalized Earnings Yield | 2.021 |